GeoVax Labs, Inc. develops vaccines and immunotherapies for infectious diseases and cancer. Company news commonly covers clinical and regulatory updates for programs such as GEO-CM04S1, a next-generation COVID-19 vaccine candidate, GEO-MVA for mpox and smallpox, and Gedeptin for head and neck cancer. Updates also include work around the MVA-VLP platform and MVA-VLP-MUC1, a cancer immunotherapy candidate tied to tumor-associated antigen expression.
Recurring announcements include patent and intellectual property developments, financial results and business updates, manufacturing and government-program references, investor conference participation, and capital-structure or shareholder matters reported by the company.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.